Updated as the landscape evolves

News &
Updates

Regulatory changes, research summaries, and market context for peptide therapy, tightened into an editorial feed instead of a dense archive wall.

Lead Story

Start with the most relevant update

The featured story anchors the page. Everything else is a secondary scan.

Regulatory Updates March 15, 2025

Semaglutide Shortage Ends: What It Means for Compounded GLP-1 Access

The FDA declared the semaglutide shortage resolved in early 2025, triggering enforcement action against compounding pharmacies. Here's what changed and what patients should know.

#Semaglutide #Compounding #FDA #GLP-1

Byline

Peptidely Editorial Team

Coverage stays focused on regulatory shifts, clinical signal changes, and the practical implications for patients and clinicians.

Read analysis →

Browse Archive

Recent reporting

Shorter summaries and a cleaner metadata row make the archive easier to scan.

503A BPC-157 Compounding FDA GLP-1 Regulatory Research Peptides Semaglutide

Regulatory Updates Feb 1, 2025

BPC-157 in 2025: What the FDA Prohibition Means and What Remains

The 2023 FDA prohibition of BPC-157 from 503A compounding changed the landscape for one of the most popular research peptides. Here's an honest assessment of where things stand.

#BPC-157 #Regulatory

Keep exploring

If the blog surfaces a topic you want to understand in more depth, jump into the structured reference pages.

Therapy Guides →

Long-form explainers for regulation, dosing context, compounding, and safety.

Research Hub →

Landmark studies, evidence tiers, and the most researched compounds.